- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- TC-5619-238 5mg, TC-5619-238 25mg, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD, HIV
- Interventions
- Not listed
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- ADHD
- Interventions
- Placebo, 200mg SPN-812, 400mg SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 79
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Nicotine Dependence
- Interventions
- Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Other
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Disorder With Hyperactivity
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1985 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
- Interventions
- 2 mA transcranial direct current stimulation (tDCS), 1 mA transcranial direct current stimulation (tDCS), Sham transcranial direct current stimulation (tDCS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder, Substance Abuse
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Leukemia, Lymphoma, Brain Tumor
- Interventions
- Cognitive Training Program, Control Group
- Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- d-Amphetamine Transdermal Patch, Placebo patch
- Drug
- Lead sponsor
- Noven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Irvine, California • Miami, Florida • Las Vegas, Nevada
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Experimental: methylphenidate treatment
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 45
- States / cities
- Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
- Conditions
- ADHD, Stimulant-Induced Euphoria
- Interventions
- SODAS MPH, Naltrexone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1, Placebo
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Interventions
- NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- NAT electroencephalography (EEG) test
- Other
- Lead sponsor
- Think Now Incorporated
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Berkeley, California • Los Angeles, California • Portland, Oregon
- Conditions
- ADHD
- Interventions
- Methylphenidate, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 6 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Hyperactivity Disorder Symptoms
- Interventions
- Collaborative Life Skills Intervention (CLS), Business As Usual
- Behavioral · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- OPDC-34712, Placebo, Stimulant Therapy
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Aptensio XR, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Durham, North Carolina
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- HLD100
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- SMS Intervention
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts